Allogene Therapeutics Strengthens Board Commitment with Major Stock Incentive Plan

Rhea-AI Filing Summary

Director Joshua A. Kazam of Allogene Therapeutics (ALLO) received a grant of 94,500 Restricted Stock Units (RSUs) on June 18, 2025. This represents a significant equity compensation award for the board member.

Key details of the RSU grant:

• Each RSU converts to one share of common stock
• Vesting occurs in two equal semi-annual installments over one year from grant date
• Exercise price is $0
• Vesting is contingent on continued service as director

The filing was reported via Form 4 on June 20, 2025, within the required two-business-day window for insider transaction reporting. The transaction represents a direct ownership position and was executed pursuant to the company's director compensation program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kazam Joshua A

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/18/2025		A		94,500		(1)	(1)	Common Stock	94,500	$0	94,500	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

Remarks:

Exhibits: Power of Attorney

	/s/Earl Douglas, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did Joshua Kazam receive from ALLO on June 18, 2025?

Joshua Kazam received 94,500 Restricted Stock Units (RSUs) from Allogene Therapeutics (ALLO) on June 18, 2025. Each RSU represents a contingent right to receive one share of the Company's Common Stock.

What is the vesting schedule for ALLO director Joshua Kazam's RSU grant?

The RSUs will vest in two equal semi-annual installments over a one-year period from the date of grant (June 18, 2025), subject to continued service through the vesting date.

What position does Joshua Kazam hold at ALLO according to the Form 4?

According to the Form 4 filing, Joshua Kazam serves as a Director of Allogene Therapeutics (ALLO), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What was the exercise price of the RSUs granted to ALLO's director?

The RSUs were granted at $0 cost to Joshua Kazam, as indicated in the 'Price of Derivative Security' column in Table II of the Form 4 filing.

Who signed the Form 4 filing for ALLO's Joshua Kazam?

The Form 4 was signed by Earl Douglas as Attorney-in-Fact for Joshua Kazam on June 20, 2025.